Overview

Where the power of nature meets the logic of science for the betterment of health.
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and acquire early stage, ingredient technologies that are protected by intellectual property.... More »

Stock Quote
NASDAQ - CDXC
Price$2.40
Change (%) Stock is Up 0.06 (2.56%)
Volume9,955
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
DateTitle 
12/01/16ChromaDex to Present at the 3rd Annual Bernstein Consumer Summit on December 8, 2016
IRVINE, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that its Chief Executive Officer and Founder, Frank Jaksch, will present at the 3rd Annual Bernstein Consumer Summit. The investor summit will be held on Dec. 7-8, 2016 at the New York Hilt... 
Printer Friendly Version
11/11/16ChromaDex Announces the Results of Pre-IND meeting for Nicotinamide Riboside for Cockayne Syndrome
IRVINE, Calif., Nov. 11, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it has completed a pre-IND meeting with the U.S. Food and Drug Administration (FDA) on Nov. 1, 2016. During the meeting, ChromaDex and the FDA discussed the development plan for nicotina... 
Printer Friendly Version
11/10/16ChromaDex Reports Third Quarter 2016 Financial Results
-Company Reports Revenue of $21.2 million for first 9 months 2016 and is on track for another record revenue year -Company Reports Revenue of $5.0 million for Q3 2016 -Accelerating trend of peer-reviewed research validating NR continued during Q3 IRVINE, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sp... 
Printer Friendly Version
Upcoming EventsMore »

There are currently no events scheduled.

What's New
Download Documentation2016 Q3 Quarterly Report on Form 10Q
Download Documentation2016 Q2 Quarterly Report on Form 10Q
Download DocumentationShareholder Letter
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.